Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights.

Rocket Lab USA, Inc. (“Rocket Lab” or the “Company”) (Nasdaq: RKLB), a leading launch provider and space systems company, today announced it has scheduled the next Electron launch for Kinéis, a global Internet-of-Things (IoT) connectivity provider.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy. Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD), to predict cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, proudly announces that Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, has reached a remarkable milestone of successfully completing 100 MWA procedures for thyroid nodules. This achievement underscores both the growing adoption of MWA and the transformative potential of the technology in treating thyroid conditions.